Thursday, July 23, 2020 1:31:06 PM
ARAV Aravive price target raised to $26 from $15 at H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis raised the firm's price target on Aravive to $26 from $15 and keeps a Buy rating on the shares after the company announced the completion of its Phase 1b trial testing AVB-500 in patients with platinum-resistant ovarian cancer. As expected, these data confirmed prior observations of safety and efficacy and provided key information for the design of the upcoming Phase 2/3 trial, Pantginis tells investors in a research note.
FEATURED Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • Sep 24, 2024 8:50 AM
FEATURED Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM